Zobrazeno 1 - 10
of 25
pro vyhledávání: '"MT Pulido-Rios"'
Autor:
S. Jaw-Tsai, MT Pulido-Rios, Sharath S. Hegde, William J. Martin, Yuhua Ji, Alexander McNamara, Glenmar P. Obedencio
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 346:241-250
Tiotropium is currently the only once-daily, long-acting muscarinic antagonist (LAMA) approved in the United States and other countries for the treatment of chronic obstructive pulmonary disease (COPD). Glycopyrronium has shown promise as a LAMA and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2fee814ddda2b900ee4e73ec56cb80eb
https://doi.org/10.1124/jpet.113.203554
https://doi.org/10.1124/jpet.113.203554
Autor:
Alexander McNamara, Mathai Mammen, William J. Martin, Sharath S. Hegde, Eric L. Stangeland, MT Pulido-Rios, Tod Steinfeld
Publikováno v:
Pulmonary pharmacologytherapeutics. 25(5)
Combinations of a muscarinic receptor antagonist (MA) and a β(2)-adrenoceptor agonist (BA) improve bronchodilation in COPD patients to a greater extent than drugs with either mechanism alone. Here, using an in vivo model of bronchoprotection in guin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28d80e094f24ab8705495a6ac0ce3e75
https://pubmed.ncbi.nlm.nih.gov/22766316
https://pubmed.ncbi.nlm.nih.gov/22766316
Publikováno v:
Journal of pharmacological and toxicological methods. 63(1)
Introduction The discovery of novel bronchodilators that treat human respiratory disorders has been guided by an array of animal models of bronchoconstriction which differ in technical complexity and experimental endpoints. Here, we apply methodology
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2604f9362263b10a075a14285e605735
https://pubmed.ncbi.nlm.nih.gov/20594937
https://pubmed.ncbi.nlm.nih.gov/20594937
Publikováno v:
C49. COPD: PHARMACOLOGICAL TREATMENT LAMA.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c603c05ca4bbb9bf8589a45396e0e765
https://doi.org/10.1164/ajrccm-conference.2009.179.1_meetingabstracts.a4557
https://doi.org/10.1164/ajrccm-conference.2009.179.1_meetingabstracts.a4557
Autor:
T Steinfeld, K Chin, R Thomas, Sharath S. Hegde, JR Jasper, TW Lee, M Mammen, MT Pulido-Rios, J Aiyar
Publikováno v:
C49. COPD: PHARMACOLOGICAL TREATMENT LAMA.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::141547f5182b146a264437d31d5c9d7c
https://doi.org/10.1164/ajrccm-conference.2009.179.1_meetingabstracts.a4552
https://doi.org/10.1164/ajrccm-conference.2009.179.1_meetingabstracts.a4552
Autor:
TW Lee, T Steinfeld, Y Ji, K King, JX Huang, JR Jasper, M Mammen, MT Pulido-Rios, K Chin, Sharath S. Hegde
Publikováno v:
C49. COPD: PHARMACOLOGICAL TREATMENT LAMA.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f013cd7e59339f4cb0ca80223e16b061
https://doi.org/10.1164/ajrccm-conference.2009.179.1_meetingabstracts.a4553
https://doi.org/10.1164/ajrccm-conference.2009.179.1_meetingabstracts.a4553
Publikováno v:
D102. CHRONIC OBSTRUCTIVE PULMONARY DISEASE PHARMACOTHERAPY.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2e2c9603a91b1831b000e62a4ca6badd
https://doi.org/10.1164/ajrccm-conference.2009.179.1_meetingabstracts.a6195
https://doi.org/10.1164/ajrccm-conference.2009.179.1_meetingabstracts.a6195
Autor:
J Trumbull, MT Pulido-Rios, William J. Martin, Glenmar P. Obedencio, S Jaw-Tsai, K Kwan, F Zamora, Sharath S. Hegde, A McNamara
Publikováno v:
C49. COPD: PHARMACOLOGICAL TREATMENT LAMA.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b8da996b817e3f92a1c1196729c3c311
https://doi.org/10.1164/ajrccm-conference.2009.179.1_meetingabstracts.a4551
https://doi.org/10.1164/ajrccm-conference.2009.179.1_meetingabstracts.a4551
Autor:
Travis Renner, Scott Armstrong, Sharath S. Hegde, Richard Wilson, MT Pulido-Rios, Adam D. Hughes, Harold Thibodeaux, Mathai Mammen, Glenmar P. Obedencio, Jeffrey R. Jasper, Alexander McNamara, Tod Steinfeld, Shelley Sweazey
Publikováno v:
European journal of pharmacology. 605(1-3)
Existing antimuscarinic drugs for overactive bladder have high affinity for M(3)/M(1) muscarinic receptors and consequently produce M(3)/M(1)-mediated adverse effects including dry mouth, constipation, mydriasis and somnolence. TD-6301 is a M(2/4) mu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::896e9d329b3ca063d21043ac5af99398
https://pubmed.ncbi.nlm.nih.gov/19168050
https://pubmed.ncbi.nlm.nih.gov/19168050
Autor:
Sandborn WJ; Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA., Nguyen DD; Theravance Biopharma US, Inc., South San Francisco, CA, USA., Beattie DT; Theravance Biopharma US, Inc., South San Francisco, CA, USA., Brassil P; Theravance Biopharma US, Inc., South San Francisco, CA, USA., Krey W; Theravance Biopharma US, Inc., South San Francisco, CA, USA., Woo J; Theravance Biopharma US, Inc., South San Francisco, CA, USA., Situ E; Theravance Biopharma US, Inc., South San Francisco, CA, USA., Sana R; Theravance Biopharma US, Inc., South San Francisco, CA, USA., Sandvik E; Theravance Biopharma US, Inc., South San Francisco, CA, USA., Pulido-Rios MT; Theravance Biopharma US, Inc., South San Francisco, CA, USA., Bhandari R; Delta Research Partners, Monroe, LA, USA., Leighton JA; Department of Medicine, Mayo Clinic Arizona, Scottsdale, AZ, USA., Ganeshappa R; Pinnacle Clinical Research, San Antonio, TX, USA., Boyle DL; Biomarker Laboratory, University of California San Diego, La Jolla, CA, USA., Abhyankar B; Theravance Biopharma Ireland Limited, Dublin, Ireland., Kleinschek MA; Theravance Biopharma US, Inc., South San Francisco, CA, USA., Graham RA; Theravance Biopharma US, Inc., South San Francisco, CA, USA., Panes J; Department of Gastroenterology, Hospital Clinic Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain.
Publikováno v:
Journal of Crohn's & colitis [J Crohns Colitis] 2020 Sep 16; Vol. 14 (9), pp. 1202-1213.